These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26205647)

  • 1. Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
    Vinicola V; Giampà E; Di Bonito M; Ferretti V; Nuvoli G; Paoletti F; Piazzini M; Ranieri M; Tuveri MA
    Minerva Endocrinol; 2015 Sep; 40(3):187-93. PubMed ID: 26205647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
    Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT; Safi W; Trinh H
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of adherence to osteoporosis treatment in clinical practice.
    Rossini M; Bianchi G; Di Munno O; Giannini S; Minisola S; Sinigaglia L; Adami S;
    Osteoporos Int; 2006; 17(6):914-21. PubMed ID: 16538553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.